Hemophilia A Gene Therapy Race Intensifies With Updated Sangamo/Pfizer Data

Sangamo and Pfizer released positive Phase I/II data from a cohort of patients treated with a higher dose of the gene therapy SB-525 for hemophilia A, but rivals are further ahead in development.